Benzinga | Aug 6, 2020 05:43PM EDT

Bellicum Pharmaceuticals Q2 EPS $(8.55)

Bellicum Pharmaceuticals (NASDAQ:BLCM) reported quarterly losses of $(8.55) per share which missed the analyst consensus estimate of $(3.33) by 156.76 percent. This is a 1374.14 percent decrease over losses of $(0.58) per share from the same period last year.